Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

NCT05879367 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma, IDH-wildtype
Glioblastoma
Glioblastoma Multiforme
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
GBM
Astrocytoma
Astrocytoma, IDH-Mutant

Interventions

DRUG: Eflornithine (Dose Level 1)
DRUG: Eflornithine (Dose Level 2)
DRUG: Eflornithine (Dose Level -1)
DRUG: Temozolomide

Sponsor

Orbus Therapeutics, Inc.